Regeneron (REGN) Gets a Buy Rating from Argus Research

By Jason Carr

In a report released today, Jasper Hellweg from Argus Research maintained a Buy rating on Regeneron (REGNResearch Report), with a price target of $540.00. The company’s shares closed last Monday at $447.80.

According to, Hellweg is a 1-star analyst with an average return of -4.2% and a 41.2% success rate. Hellweg covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Vertex Pharmaceuticals, and HCA Healthcare.

Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $465.00, implying a 4.6% upside from current levels. In a report issued on February 26, Canaccord Genuity also upgraded the stock to Buy with a $550.00 price target.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $51.24B and has a P/E ratio of 25.17. The company has a Price to Book ratio of 4.62.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Last month, George Sing, a Director at REGN sold 2,500 shares for a total of $1,150,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.